Your mother is 78 and has her flu shot booked at the pharmacy next week. A friend forwards her a post claiming that thymosin alpha-1, a small immune peptide, “supercharges” vaccines for seniors. Is there real evidence that it makes a flu shot work better in older people?
There is some, but it is small, mostly decades old, and it measured antibodies in the blood rather than whether people actually caught the flu. A 1989 trial in 90 older veterans reported a stronger antibody response when thymosin alpha-1 was given alongside the vaccine. A 2012 pilot in dialysis patients saw higher antibody levels three weeks after vaccination that faded faster afterward. No study showed fewer flu illnesses or hospital stays, and thymosin alpha-1 is not an FDA-approved drug in the United States. The step with proven value is the flu vaccine itself.
The problem researchers were trying to solve
Older immune systems tend to respond less strongly to vaccines. In a 1984 study, Ershler and colleagues measured antibodies after the 1983-1984 flu vaccine and found clearly lower responses in elderly volunteers than in young ones. They then grew white blood cells from both groups in lab dishes. Adding thymosin raised antibody production, and the boost was larger in cells from the older volunteers. That was a laboratory finding, and the authors framed it as a reason to run a clinical trial rather than as proof of benefit.
What the trials in people measured
The clinical trial followed in 1989, from Gravenstein, Ershler and colleagues at a Veterans Affairs hospital in Wisconsin. Ninety men aged 65 to 99, with an average age of about 77, were randomly assigned to thymosin alpha-1 or a placebo, given with the 1986 flu vaccine, and neither the men nor the staff knew who got which. Blood from 85 men could be analyzed. The researchers counted a response as a fourfold rise in flu antibodies over the following three to six weeks, and they looked separately at men younger and older than 77. No side effects were seen in either group. The paper’s title reports an augmented antibody response with thymosin, but the public abstract is cut off before the numbers, so we cannot tell you how large the difference was.
The second trial, led by Carraro in Padua, Italy, enrolled people on hemodialysis, whose kidney failure weakens their response to vaccines. They received the 2009 pandemic H1N1 vaccine with an added booster ingredient, either alone or together with thymosin alpha-1 at one of two strengths. Among 94 patients, both thymosin groups had higher antibody levels at day 21 and met the European regulators’ benchmarks for a pandemic vaccine. By day 42, though, antibody levels in the thymosin groups had dropped more steeply than in the vaccine-only group. No side effects were linked to thymosin, and the authors called it a pilot needing larger studies.
A 2011 review by an Italian team involved in this research concluded that thymosin alpha-1 looked promising as an add-on but that further studies were needed. That remains the honest summary.
What to do before flu season
An antibody rise in a blood test is an encouraging signal, not proof that someone is better protected. These studies were small, used vaccines from earlier decades, and the published summaries report antibody results, not flu cases, pneumonia, or hospital stays. They used a pharmaceutical product given by study doctors. Research-catalog thymosin alpha-1 vials are marked not for human use, differ from the trial product, and this record gives no reason to order one.
The useful action is simpler. MedlinePlus notes that people 65 and older are at higher risk of flu complications, that the CDC recommends a yearly flu shot for nearly everyone 6 months and older, and that some vaccines are made especially for people 65 and older. Ask the pharmacist which version fits your parent, and get it on schedule. Not medical advice.
Sources
- Gravenstein S et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Am Geriatr Soc, 1989 (PubMed)
- Carraro G et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine, 2012 (PubMed)
- Ershler WB et al. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol, 1984 (PubMed)
- Panatto D et al. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. J Prev Med Hyg, 2011 (PubMed, review)
- MedlinePlus: Flu Shot
Related reading
- Our guide to who should get a flu vaccine, and when
- The U.S. approval gap behind thymosin alpha-1 ads
- What the ICU sepsis trial of thymosin alpha-1 found
By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-23 PT. Not medical advice.